Study: NCT06135714

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic therapy for 12 weeks after primary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy for 12 weeks after primary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy (SBRT/conventional RT)
Description: Brain: 18-24Gy/1Fr. or 27Gy/3Fr. or 30Gy/5Fr. Lung: 42Gy/4Fr.(peripheral) or 50Gy/8Fr.(central) or 60Gy/25Fr.(ultra central) Liver/Adrenal: 40Gy/5Fr. Bone: 35Gy/5Fr. Distant lymph node: 45/10Fr. or 60Gy/25Fr.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for the oligometastases

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Same systemic therapy after secondary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Same systemic therapy after secondary registration
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib